Detect Disease Biomarkers Articles & Analysis
30 news found
Ward Detwiler, our President & CEO, had the opportunity to speak about how STAGE is innovating the world of MR at MedTech Strategist Innovation 2021. ...
This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the most common biomarker used for HCC ...
The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. ...
The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. ...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and ...
Biomarker detection can provide insight into the mechanism of action or resistance of new drugs in disease models. Creative Proteomics can provide detection services for cytokines and biomarkers for the majority of pharmaceutical R&D personnel. Its Cytokine division has complete infrastructure and ...
“The ADDF created the Diagnostics Accelerator to support research into promising biomarkers that will play a crucial role in research, diagnosis, and treatment of Alzheimer’s disease. ...
CAC is a recognized vital biomarker for detection of cardiovascular disease. Nanox.AI believes that early detection and subsequent treatment of cardiovascular disease has the potential to significantly decrease the morbidity and mortality of this highly prevalent condition. ...
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS, for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with Colli-Pee. Novosanis hereby offers a solution for applications in the field of oncology research and ...
We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine. The grant awards the most impactful proposal in cancer related research using urine as a sample type, which has shown to be an emerging non-invasive liquid biopsy. For urine sample collection, the Colli-Pee device will be provided by ...
X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide. Previously exclusive to X-ZELL, the patented system is part of the company’s single-cell diagnostics platform, which is capable of isolating and visualising individual atypical cells from a small 10mL blood sample. According to X-ZELL’s Head of Engineering ...
Award-winning Singaporean start-up, X-ZELL, has announced the formation of a new, interdisciplinary Imaging Technology division. The announcement comes on the back of a new collaboration agreement with Finnish Artificial Intelligence (AI) specialist, Aiforia Technologies, and is part of the ongoing digitisation of X-ZELL’s patented rare cell detection technology. X-ZELL’s modular ...
Research grant of (up to) € 25 000 in support of the most impactful proposal and (up to) 200 Colli-Pee urine collection devices for use with the project. Novosanis is offering a research grant exclusive to EACR members to stimulate innovative research in cancer biomarker detection using urine as a sample type. As urine sampling is easy, quick and non-invasive it has the potential to change ...
The study by Laura Téblick (University of Antwerp, Belgium) investigated whether varying first-void urine collection volumes, including 4, 10 and 20 mL collected with Colli-Pee, affects the detection of human and viral endpoints (i.e., glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (ACTB), β-globin (HBB) and Human Papillomavirus (HPV). The results showed that all ...
The majority of these referrals appear unnecessary because the HPV positive cytology positive tested women often harbor an infection that will not cause high grade disease or cancer, but in fact carry a very low risk for severe disease. ...
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP. Analysis of blood samples from CAMP, the largest study yet ...
LC-SCRUM-Asia, a leading cancer genomic screening program, has selected Thermo Fisher Scientific's Ion Torrent Genexus System* and Oncomine Precision Assay*, a pan-cancer panel, to advance precision medicine in Asia. The next-generation sequencing (NGS) solutions will be used in two prospective, observational projects to support the development of future therapeutics and diagnostics for non-small ...
Bodyport, the digital health company focused on the detection and management of heart disease, today announced the close of an $11.2 million Series A investment round. ...
Thermo Fisher Scientific today announced that it has expanded its strategic partnership with Agios Pharmaceuticals by adding the co-development of a second companion diagnostic (CDx) for oncology to their existing agreement. The CDx will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System, and will be used globally to identify low-grade glioma (LGG) patients ...
Lauder, Bill Gates, Jeff Bezos and MacKenzie Bezos, the Dolby family, the Charles and Helen Schwab Foundation, and others to speed up development of biomarkers for early detection of Alzheimer's and related dementias The Alzheimer’s Drug Discovery Foundation (ADDF) today announced five new research investments through its Diagnostics ...